Drug intelligence / Profile preview

CX13

Development stage: Preclinical
Lead developer: Hangzhou Bangshun Pharmaceutical
Modality: Small Molecules

Overview

CX13 is a preclinical-stage small molecule targeting the peroxisome proliferator-activated receptor gamma (PPARG), currently under development by Hangzhou Bangshun Pharmaceutical (also known as Biosun Pharma). The drug is being developed as a monotherapy for the treatment of solid tumors. PPARG is a nuclear receptor that regulates gene expression involved in cell differentiation, lipid metabolism, and inflammation; in the context of oncology, modulating PPARG signaling is explored for its potential to inhibit tumor growth and alter the tumor microenvironment. Hangzhou Bangshun Pharmaceutical holds global commercial rights to the asset and expects to submit an Investigational New Drug (IND) application in 2027.

Other names: CX13CX-13CX 13

Targets

PPARG (Peroxisome proliferator-activated receptor gamma)

Beyond the preview

Go deeper on CX13.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CX13.

Explore the full profile